(NASDAQ: LEXX) Lexaria Bioscience's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 12.04%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 36.28%.
Lexaria Bioscience's earnings in 2026 is -$10,793,149.On average, 4 Wall Street analysts forecast LEXX's earnings for 2026 to be -$9,138,670, with the lowest LEXX earnings forecast at -$11,219,261, and the highest LEXX earnings forecast at -$6,794,273. On average, 3 Wall Street analysts forecast LEXX's earnings for 2027 to be -$7,869,410, with the lowest LEXX earnings forecast at -$7,560,806, and the highest LEXX earnings forecast at -$8,100,864.
In 2028, LEXX is forecast to generate -$7,107,855 in earnings, with the lowest earnings forecast at -$6,829,115 and the highest earnings forecast at -$7,316,909.